<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519648</url>
  </required_header>
  <id_info>
    <org_study_id>RIFI</org_study_id>
    <nct_id>NCT01519648</nct_id>
  </id_info>
  <brief_title>A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hematological Society, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hematological Society, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimate the rate of occurrence of Invasive Fungal Infections (IFIs) in patients with acute
      leukemia for the first 6 months of chemotherapy (that usually correspond to four courses of
      chemotherapy), and hematopoietic stem cells transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center observational study of IFI in high risk hematological patients, the study
      will investigate the epidemiology of IFI, describe antifungal strategy, proportion of
      antifungal prophylaxis, empiric therapy, pre-emptive therapy and targeted therapy in at-risk
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Invasive Fungal Infections</measure>
    <time_frame>6 month</time_frame>
    <description>Estimate the rate of IFIs in patients with acute leukemia for the first 6 months of chemotherapy (that usually correspond to four courses of chemotherapy), and hematopoietic stem cells transplantation.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">808</enrollment>
  <condition>Invasive Fungal Infections</condition>
  <arm_group>
    <arm_group_label>Acute leukemia patients</arm_group_label>
    <description>Patients with de novo or relapsed acute myeloid and lymphoid leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allo- or auto- transplant recipients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This observational study will be implemented in the hematology departments or hematology
        centers with or without HSCT located throughout Russia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with de novo or relapsed AL (AML, ALL)started chemotherapy

          -  All newly allogeneic or autologous transplant recipients during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galina A Klyasova</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Hematological Society</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <results_first_submitted>June 18, 2014</results_first_submitted>
  <results_first_submitted_qc>June 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2014</results_first_posted>
  <last_update_submitted>July 18, 2014</last_update_submitted>
  <last_update_submitted_qc>July 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasive fungal infection</keyword>
  <keyword>Acute leukemia (AL)</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <keyword>Antifungal stewardship</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Hematological malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute Leukemia Patients</title>
          <description>Patients with de novo or relapsed acute myeloid and lymphoid leukemia</description>
        </group>
        <group group_id="P2">
          <title>Allo- or Auto- Transplant Recipients</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acute Leukemia Patients</title>
          <description>Patients with de novo or relapsed acute myeloid and lymphoid leukemia</description>
        </group>
        <group group_id="B2">
          <title>Allo- or Auto- Transplant Recipients</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="502"/>
            <count group_id="B2" value="306"/>
            <count group_id="B3" value="808"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="1-79" lower_limit="1" upper_limit="79"/>
                    <measurement group_id="B2" value="37" spread="1-66" lower_limit="1" upper_limit="66"/>
                    <measurement group_id="B3" value="40" spread="1-79" lower_limit="1" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Invasive Fungal Infections</title>
        <description>Estimate the rate of IFIs in patients with acute leukemia for the first 6 months of chemotherapy (that usually correspond to four courses of chemotherapy), and hematopoietic stem cells transplantation.</description>
        <time_frame>6 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acute Leukemia Patients</title>
            <description>Patients with de novo or relapsed acute myeloid and lymphoid leukemia</description>
          </group>
          <group group_id="O2">
            <title>Allo- or Auto- Transplant Recipients</title>
            <description>Allo- or auto- transplant recipients</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Invasive Fungal Infections</title>
          <description>Estimate the rate of IFIs in patients with acute leukemia for the first 6 months of chemotherapy (that usually correspond to four courses of chemotherapy), and hematopoietic stem cells transplantation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.872</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.237</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.178</ci_lower_limit>
            <ci_upper_limit>2.977</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The study was observational and the adverse events were not evaluated</desc>
      <group_list>
        <group group_id="E1">
          <title>Acute Leukemia Patients</title>
          <description>Patients with de novo or relapsed acute myeloid and lymphoid leukemia</description>
        </group>
        <group group_id="E2">
          <title>Allo- or Auto- Transplant Recipients</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Galina A Klyasova</name_or_title>
      <organization>National Hematological Society</organization>
      <phone>+7(495)6125181</phone>
      <email>klyasova.g@blood.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

